The rise of multi-drug resistant bacteria globally has led to the "doomsday of antibiotics" rapidly approaching. It has led to many well-publicized calls for global funding to develop new antimicrobial drugs. Throughout evolution, phages have continuously adapted in lytic infection cycles to fight their bacterial hosts in an arms race. Phages use complex molecular mechanisms to hijack bacterial cell metabolism to produce progeny viral particles. The tightly intertwined relationship leads to the emergence of highly specific and evolutionarily optimized molecular interactions, thus representing a unique source for the identification of new potential antimicrobial targets. With advances in high-throughput genome sequencing, tens of thousands of phage genomes have been sequenced. And some researchers search a large number of phage genomes from bacteria to find gene products that inhibit bacteria, so as to identify new targets of antibacterial agents, which can inspire the screening and design of new small molecule compounds.
Fig 1. Phage-based target discovery and its exploitation in the development of novel antibacteria. (Wan X, et al., 2021) Antimicrobial drug discovery is limited by many obstacles, including failure to identify new culturable microorganisms, toxic compounds in synthetic compound libraries, and more. Researchers in our department bypass some of these barriers through bacteriophage genomics, high-throughput screening, while identifying novel antibacterial agents with antiviral or immunomodulatory efficacy and evaluating toxicity and efficacy.
We apply the concept of phage-mediated bacterial growth inhibition to antibiotic discovery. Our investigators sequenced a large number of phages and identified a novel family of polypeptides that inhibited growth when expressed in S. aureus. Our investigators searched the genomes of large numbers of bacteriophages for gene products that inhibit bacteria to identify novel targets for antibacterial agents.
Creative Biolabs can meet the needs of customers by providing antimicrobial drugs development solutions on time and on budget. We have in-depth knowledge and experience of the tools and processes involved in the phage projects. Our skilled and dedicated scientific researchers ensure that the most suitable methods and techniques are selected for your project. If necessary, please feel free to contact us.
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
